Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles

Regulated portals of entry into the cell

Conner, S. D., & Schmid, S. L. (2003) · Nature · doi:10.1038/nature01451 · Cited by 3,958

Arzneimittelforschung

Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,286

Mechanisms of phagocytosis in macrophages

Aderem, A., & Underhill, D. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.593 · Cited by 2,854

Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles

He, C., Hu, Y., Yin, L., Tang, C., & Yin, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.065 · Cited by 2,607

Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase

McKinney, J. D., zu Bentrup, K. H., Muñoz‐Elías, E. J., Miczák, A., Chen, B., Chan, W.-T., Swenson, D. L., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,361

RESPONSE OF CULTURED MACROPHAGES TO MYCOBACTERIUM TUBERCULOSIS , WITH OBSERVATIONS ON FUSION OF LYSOSOMES WITH PHAGOSOMES

Armstrong, J. A., & Hart, P. D. (1971) · The Journal of Experimental Medicine · doi:10.1084/jem.134.3.713 · Cited by 991

A Coat Protein on Phagosomes Involved in the Intracellular Survival of Mycobacteria

Ferrari, G., Langen, H., Naito, M., & Pieters, J. (1999) · Cell · doi:10.1016/s0092-8674(00)80754-0 · Cited by 586

CELL BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS PHAGOSOME

Vergne, I., Chua, J., Singh, S., & Deretic, V. P. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.114015 · Cited by 440

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

Pandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318

Oral solid lipid nanoparticle-based antitubercular chemotherapy

Pandey, R., Sharma, S., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2005.08.009 · Cited by 271

Mechanisms of phagocytosis

Allen, L. H., & Aderem, A. A. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80102-6 · Cited by 267

Therapeutic potential of nanoparticulate systems for macrophage targeting

Chellat, F., Merhi, Y., Moreau, A., & Yahia, L. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.05.044 · Cited by 237

Delivery systems to increase the selectivity of antibiotics in phagocytic cells

Briones, E., Colino, C. I., & Lanao, J. M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.10.027 · Cited by 226

The Trojan horse: survival tactics of pathogenic mycobacteria in macrophages

Nguyen, L., & Pieters, J. (2005) · Trends in Cell Biology · doi:10.1016/j.tcb.2005.03.009 · Cited by 204

Non-invasive pulmonary aerosol delivery in mice by the endotracheal route

Bivas‐Benita, M., Zwier, R., Junginger, H. E., & Borchard, G. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.04.009 · Cited by 201

Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification

Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.1.0010 · Cited by 190

Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages

Hirota, K., Hasegawa, T., Hinata, H., Ito, F., Inagawa, H., Kochi, C., Soma, G., Makino, K., & Terada, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.01.013 · Cited by 182

Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile

Nafee, N. A., Schneider, M., Schaefer, U. F., & Lehr, C. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.049 · Cited by 176

Alkaline Phosphatase: A Marker of Alveolar Type II Cell Differentiation

Edelson, J. D., Shannon, J. M., & Mason, R. J. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.5.1268 · Cited by 173

Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections

Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.011 · Cited by 164

Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats

Wijagkanalan, W., Kawakami, S., Takenaga, M., Igarashi, R., Yamashita, F., & Hashida, M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.10.011 · Cited by 159

Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes

Chono, S., Tanino, T., Seki, T., & Morimoto, K. (2006) · Journal of drug targeting · doi:10.1080/10611860600834375 · Cited by 155

Drug Treatment for Tuberculosis during Pregnancy

Bothamley, G. H. (2001) · Drug Safety · doi:10.2165/00002018-200124070-00006 · Cited by 152

Delivery of rifampicin–PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis

Hirota, K., Hasegawa, T., Nakajima, T., Inagawa, H., Kohchi, C., Soma, G., Makino, K., & Terada, H. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.020 · Cited by 130

Isolation of highly pure alveolar epithelial type I and type II cells from rat lungs

Chen, J., Chen, Z., Narasaraju, T. A., Jin, N., & Liu, L. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700095 · Cited by 114

Inhalable Microparticles as Carriers for Pulmonary Delivery of Thymopentin-Loaded Solid Lipid Nanoparticles

Li, Y., Sun, X., Gong, T., Liu, J., Zuo, J., & Zhang, Z. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0201-z · Cited by 103

Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection

Zahrt, T. C. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(02)00083-7 · Cited by 87

Determination of rifampicin and its main metabolite in plasma and urine in presence of pyrazinamide and isoniazid by HPLC method

Panchagnula, R., Sood, A., Sharda, N., Kaur, K., & Kaul, C. L. (1999) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/s0731-7085(98)00112-5 · Cited by 73

Histochemical and Immunocytochemical Identification of Alveolar Type II Epithelial Cells Isolated from Fetal Rat Lung

Post, M., & Smith, B. T. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/137.3.525 · Cited by 68

Innate immune responses to M. tuberculosis infection

Natarajan, K., Kundu, M., Sharma, P., & Basu, J. (2011) · Tuberculosis · doi:10.1016/j.tube.2011.04.003 · Cited by 56

The behavior of PLGA microspheres containing rifampicin in alveolar macrophages

Onoshita, T., Shimizu, Y., Yamaya, N., Miyazaki, M., Yokoyama, M., Fujiwara, N., Nakajima, T., Makino, K., Terada, H., & Haga, M. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.10.036 · Cited by 54

Evaluation of cytotoxic effects and oxidative stress with hydroxyapatite dispersions of different physicochemical properties in rat NR8383 cells and primary macrophages

Albrecht, C., Scherbart, A. M., van Berlo, D., Braunbarth, C. M., Schins, R. P. F., & Scheel, J. (2009) · Toxicology in Vitro · doi:10.1016/j.tiv.2009.01.005 · Cited by 49

Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.

Pallanza, R., Arioli, V., Fürész, S., & Bolzoni, G. (1967) · PubMed · Cited by 47

Cellular targeting and trafficking of drug delivery systems for the prevention and treatment of MTb

Lawlor, C., Kelly, C., O’Leary, S. M., O’Sullivan, M. P., Gallagher, P., Keane, J., & Cryan, S. (2011) · Tuberculosis · doi:10.1016/j.tube.2010.12.001 · Cited by 32

Novel isolation and purification method permitting functional cytotoxicity studies of macrophages from milky spots in the greater omentum

Krist, L. F. G., Kerremans, M., Koenen, H. J. P. M., Blijleven, N., Eestermans, I. L., Calame, W., Meyer, S., & Beelen, R. H. J. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00096-s · Cited by 17

Drug Treatment of Tuberculosis: I. Standard Chemotherapy

Crofton, J. (1960) · BMJ · doi:10.1136/bmj.2.5195.370 · Cited by 15

Preparation of Rifampicin-solid lipid nanoparticles and evaluation of their cell specificity

Zhang, Z. (2011) · Huaxi yaoxue zazhi · Cited by 1

Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles

Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645

Nanotechnology approaches for global infectious diseases

Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520

Nanoparticle-Mediated Pulmonary Drug Delivery: A Review

Paranjpe, M., & Müller-Goymann, C. C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045852 · Cited by 467

Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – A systematic review of in vitro data

Doktorovová, S., Souto, E. B., & Silva, A. M. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.02.005 · Cited by 419

Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery

Liu, Q., Guan, J., Lu, Q., Zhang, X., & Mao, S. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.023 · Cited by 239

Lipid Microsphere Formulation Containing Rifampicin Targets Alveolar Macrophages

Takenaga, M., Ohta, Y., Tokura, Y., Hamaguchi, A., Igarashi, R., Disratthakit, A., & Doi, N. (2008) · Drug Delivery · doi:10.1080/10717540801952530 · Cited by 23

Mannose-Decorated Solid-Lipid Nanoparticles for Alveolar Macrophage Targeted Delivery of Rifampicin

Bera, H., Zhao, C., Tian, X., Cun, D., & Yang, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16030429 · Cited by 35

Rifampicin Loaded Mannosylated Cationic Nanostructured Lipid Carriers for Alveolar Macrophage-specific Delivery

Song, X. C., Lin, Q., Guo, L. H., Fu, Y. S., Han, J., Ke, H., Sun, X., Gong, T., & Zhang, Z. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1572-3 · Cited by 82

Preparation of Rifampicin-solid lipid nanoparticles and evaluation of their cell specificity

Zhang, Z. (2011) · Huaxi yaoxue zazhi · Cited by 1

Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages

Vieira, A. C. C., Chaves, L. L., Pinheiro, M., Lima, S. A. C., Ferreira, D., Sarmento, B. F. C. C., & Reis, S. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1434186 · Cited by 92